A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 79 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-12.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 30th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 62nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 53rd largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 85 in phase 3, and was the 140th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Participants will receive TCZ 162 milligrams (mg) SC every week (QW) or every 2 weeks (Q2W) for up to 96 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
Drug: Tocilizumab
Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
Drug: Tocilizumab
TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
Also known as: RoActemra/Actemra
Number of Participants With at Least One Serious Adverse Event (SAE)
Adverse events (AEs) were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The number of participants with at least one SAE regardless of treatment relationship was reported.
Time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants With at Least One SAE
AEs were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The percentage of participants with at least one SAE regardless of treatment relationship was calculated.
Time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
Time frame: From Baseline to 8 weeks after last dose; assessed at Baseline; Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
Time frame: Baseline
Percentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated. Positive assay results obtained post-Baseline were further investigated via confirmation assay and a neutralization assay.
Time frame: From Week 12 up to 8 weeks after last dose; assessed at Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants Who Correctly Administered All SC TCZ Doses
Compliance was assessed using drug dispensing logs, diary cards kept by the participant, and return records, as reviewed by the Investigator at regular visits. Total compliance up to the end of treatment was defined as the percentage of participants who correctly administered all scheduled doses of SC TCZ. Correct administration was defined as proper injection technique, injection of the correct amount (162 mg), device not left at room temperature for greater than (\>) 8 hours, and absence of other medication errors.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Disease Activity Score Based on 28 Joints (DAS28) Score
The DAS28 was calculated using the Swollen Joint Count (SJC), Tender Joint Count (TJC), erythrocyte sedimentation rate (ESR), and Global Assessment of Disease Activity by the participant according to Visual Analog Scale (VAS) score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-millimeter (mm) scale to a 10-point score. The DAS28 was calculated as (0.56 multiplied by \[×\] square root of TJC) + (0.28 × square root of SJC) + (0.7 × log natural \[ln\] ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in DAS28 Score
The DAS28 was calculated using the SJC, TJC, ESR, and Global Assessment of Disease Activity by the participant according to VAS score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Clinical Disease Activity Index (CDAI) Score
The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in CDAI Score
The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Simplified Disease Activity Index (SDAI) Score
The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and high-sensitivity C-reactive protein (hsCRP) level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 milligram per deciliter (mg/dL), scores would be expected to fall within less than or equal to (≤) 77 points.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in SDAI Score
The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and hsCRP level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Tender Joint Count (TJC) Score
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in TJC Score
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of tender joints.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Swollen Joint Count (SJC) Score
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in SJC Score
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of swollen joints.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants With a DMARD Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for DMARD Dose Reduction or Interruption
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD dose reduction/interruption ≤60 days were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for DMARD Discontinuation
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD discontinuation were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants With a Corticosteroid (CCS) Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants With a CCS Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Dose Reduction
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose reduction were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Dose Interruption
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose interruption ≤14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Discontinuation
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS discontinuation \>14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was reported.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The percentage of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was calculated.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants Who Returned to the QW Regimen After Switching to the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and thereafter returned to the QW regimen was reported with the reason for returning to the QW regimen.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Time to Return to the QW Regimen After Switching to the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. Time to return was defined as the time between switching to the Q2W regimen and returning to the previous QW regimen.
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Global Assessment of Disease Activity by the Participant According to Visual Analog Scale (VAS) Score
The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in Global Assessment of Disease Activity by the Participant According to VAS Score
The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in perceived disease activity.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Global Assessment of Pain by the Participant According to VAS Score
The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in Global Assessment of Pain by the Participant According to VAS Score
The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in pain.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Heath Assessment Questionnaire-Disability Index (HAQ-DI) Score
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in HAQ-DI Score
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The change from Baseline to each visit was calculated, where positive changes represent an increased need for assistance with daily activities.
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With HAQ-DI Score <0.5
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The percentage of participants achieving a score \<0.5 was calculated at each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The number of participants who met criteria for low disease activity was reported at each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for low disease activity was calculated at each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The number of participants who met criteria for remission was reported at each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for remission was calculated at each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
| Milestone | Subcutaneous (SC) Tocilizumab (TCZ) Every 2 Weeks (Q2W) | SC TCZ Every Week (QW) | Not Treated |
|---|---|---|---|
| Started | 44 | 173 | 1 |
| Completed | 39 | 144 | 0 |
| Not completed | 5 | 29 | 1 |
| Withdrew: Adverse event or intercurrent illness | 1 | 12 | 0 |
| Withdrew: Lack of efficacy | 1 | 6 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
Adverse events (AEs) were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The number of participants with at least one SAE regardless of treatment relationship was reported.
| participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Number of Participants With at Least One Serious Adverse Event (SAE) | 4 | 19 |
AEs were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The percentage of participants with at least one SAE regardless of treatment relationship was calculated.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Percentage of Participants With at Least One SAE | 9.1 | 11.0 |
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint | 4.5 | 7.8 |
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline | 2.3 | 4.8 |
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated. Positive assay results obtained post-Baseline were further investigated via confirmation assay and a neutralization assay.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Positive Anti-TCZ Assay | 2.3 | 3.0 |
| Positive Confirmation Assay | 0 | 0.6 |
| Positive Neutralizing Assay | 0 | 0.6 |
Compliance was assessed using drug dispensing logs, diary cards kept by the participant, and return records, as reviewed by the Investigator at regular visits. Total compliance up to the end of treatment was defined as the percentage of participants who correctly administered all scheduled doses of SC TCZ. Correct administration was defined as proper injection technique, injection of the correct amount (162 mg), device not left at room temperature for greater than (\>) 8 hours, and absence of other medication errors.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Percentage of Participants Who Correctly Administered All SC TCZ Doses | 97.7 | 97.7 |
The DAS28 was calculated using the Swollen Joint Count (SJC), Tender Joint Count (TJC), erythrocyte sedimentation rate (ESR), and Global Assessment of Disease Activity by the participant according to Visual Analog Scale (VAS) score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-millimeter (mm) scale to a 10-point score. The DAS28 was calculated as (0.56 multiplied by \[×\] square root of TJC) + (0.28 × square root of SJC) + (0.7 × log natural \[ln\] ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,172) | 4.55 ± 1.732 | 4.60 ± 1.869 |
| Week 12 (n=44,172) | 3.17 ± 1.443 | 3.42 ± 1.728 |
| Week 24 (n=43,168) | 3.08 ± 1.351 | 3.35 ± 1.786 |
| Week 36 (n=39,159) | 3.07 ± 1.425 | 3.29 ± 1.624 |
| Week 48 (n=18,141) | 3.15 ± 1.392 | 3.25 ± 1.639 |
| Week 60 (n=2,92) | 4.10 ± 0.515 | 3.12 ± 1.626 |
| Week 72 (n=1,52) | 5.76 ± NA | 3.05 ± 1.970 |
| Week 84 (n=0,11) | NA ± NA | 2.78 ± 1.434 |
The DAS28 was calculated using the SJC, TJC, ESR, and Global Assessment of Disease Activity by the participant according to VAS score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,171) | -1.38 ± 1.522 | -1.19 ± 1.415 |
| Week 24 (n=43,167) | -1.42 ± 1.383 | -1.23 ± 1.692 |
| Week 36 (n=39,158) | -1.51 ± 1.312 | -1.29 ± 1.429 |
| Week 48 (n=18,140) | -1.66 ± 1.340 | -1.32 ± 1.538 |
| Week 60 (n=2,91) | 0.65 ± 1.410 | -1.29 ± 1.286 |
| Week 72 (n=1,52) | -0.35 ± NA | -1.53 ± 1.435 |
| Week 84 (n=0,10) | NA ± NA | -1.57 ± 1.312 |
The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 20.10 ± 15.467 | 23.91 ± 16.346 |
| Week 12 (n=44,172) | 13.99 ± 13.058 | 18.19 ± 14.145 |
| Week 24 (n=42,166) | 14.86 ± 13.232 | 18.03 ± 13.665 |
| Week 36 (n=39,159) | 13.26 ± 11.839 | 16.92 ± 12.598 |
| Week 48 (n=18,140) | 15.81 ± 16.479 | 16.55 ± 13.559 |
| Week 60 (n=2,92) | 13.60 ± 2.828 | 14.71 ± 11.954 |
| Week 72 (n=1,52) | 27.80 ± NA | 16.04 ± 15.476 |
| Week 84 (n=0,11) | NA ± NA | 12.82 ± 9.154 |
The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,172) | -6.11 ± 13.219 | -5.81 ± 12.010 |
| Week 24 (n=42,166) | -5.23 ± 14.134 | -5.47 ± 13.754 |
| Week 36 (n=39,159) | -7.00 ± 12.266 | -6.63 ± 10.676 |
| Week 48 (n=18,140) | -6.63 ± 13.479 | -6.70 ± 12.328 |
| Week 60 (n=2,92) | -14.05 ± 20.294 | -7.05 ± 11.065 |
| Week 72 (n=1,52) | -16.20 ± NA | -6.31 ± 12.999 |
| Week 84 (n=0,11) | NA ± NA | -10.01 ± 18.580 |
The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and high-sensitivity C-reactive protein (hsCRP) level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 milligram per deciliter (mg/dL), scores would be expected to fall within less than or equal to (≤) 77 points.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,170) | 21.54 ± 15.717 | 25.10 ± 16.972 |
| Week 12 (n=44,172) | 14.48 ± 13.058 | 18.32 ± 14.199 |
| Week 24 (n=41,166) | 15.42 ± 13.266 | 18.18 ± 13.779 |
| Week 36 (n=39,159) | 13.75 ± 11.841 | 17.06 ± 12.621 |
| Week 48 (n=18,140) | 15.85 ± 16.490 | 16.76 ± 13.603 |
| Week 60 (n=2,92) | 13.63 ± 2.841 | 14.90 ± 12.045 |
| Week 72 (n=1,52) | 27.82 ± NA | 16.23 ± 15.730 |
| Week 84 (n=0,11) | NA ± NA | 12.90 ± 9.163 |
The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and hsCRP level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,169) | -7.07 ± 13.671 | -7.00 ± 12.056 |
| Week 24 (n=41,163) | -5.71 ± 14.217 | -6.79 ± 13.069 |
| Week 36 (n=39,157) | -7.99 ± 12.858 | -7.38 ± 10.953 |
| Week 48 (n=18,139) | -8.17 ± 14.640 | -7.29 ± 12.454 |
| Week 60 (n=2,91) | -14.46 ± 20.873 | -7.52 ± 10.846 |
| Week 72 (n=1,52) | -17.04 ± NA | -7.10 ± 13.379 |
| Week 84 (n=0,10) | NA ± NA | -9.48 ± 19.290 |
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68.
| tender joints | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 13.84 ± 13.883 | 19.14 ± 18.469 |
| Week 12 (n=44,172) | 9.86 ± 11.727 | 14.06 ± 14.874 |
| Week 24 (n=42,167) | 10.95 ± 14.221 | 13.86 ± 15.176 |
| Week 36 (n=39,159) | 9.10 ± 11.392 | 13.45 ± 14.398 |
| Week 48 (n=18,141) | 10.61 ± 14.825 | 12.85 ± 16.192 |
| Week 60 (n=2,92) | 5.50 ± 0.707 | 10.47 ± 12.589 |
| Week 72 (n=1,52) | 21.00 ± NA | 11.38 ± 15.444 |
| Week 84 (n=0,11) | NA ± NA | 9.36 ± 10.984 |
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of tender joints.
| tender joints | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,172) | -3.98 ± 12.082 | -5.17 ± 12.175 |
| Week 24 (n=42,167) | -2.69 ± 12.546 | -5.12 ± 14.817 |
| Week 36 (n=39,159) | -4.03 ± 10.559 | -5.60 ± 12.402 |
| Week 48 (n=18,141) | -4.00 ± 12.902 | -5.95 ± 13.899 |
| Week 60 (n=2,92) | -9.00 ± 12.728 | -6.23 ± 10.672 |
| Week 72 (n=1,52) | -3.00 ± NA | -4.98 ± 11.514 |
| Week 84 (n=0,11) | NA ± NA | -6.27 ± 13.835 |
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66.
| swollen joints | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 9.07 ± 8.877 | 10.83 ± 10.855 |
| Week 12 (n=44,172) | 5.61 ± 7.144 | 7.87 ± 8.839 |
| Week 24 (n=42,167) | 5.98 ± 8.587 | 8.57 ± 8.783 |
| Week 36 (n=39,159) | 5.51 ± 8.398 | 6.92 ± 7.055 |
| Week 48 (n=18,141) | 4.78 ± 9.078 | 7.23 ± 7.870 |
| Week 60 (n=2,92) | 2.00 ± 2.828 | 6.52 ± 7.184 |
| Week 72 (n=1,52) | 2.00 ± NA | 7.98 ± 8.873 |
| Week 84 (n=0,11) | NA ± NA | 8.64 ± 8.857 |
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of swollen joints.
| swollen joints | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,172) | -3.45 ± 7.026 | -3.00 ± 8.543 |
| Week 24 (n=42,167) | -3.45 ± 8.434 | -2.31 ± 9.162 |
| Week 36 (n=39,159) | -3.33 ± 6.868 | -3.89 ± 8.134 |
| Week 48 (n=18,141) | -6.56 ± 9.332 | -3.25 ± 9.543 |
| Week 60 (n=2,92) | -8.50 ± 12.021 | -3.20 ± 8.702 |
| Week 72 (n=1,52) | -15.00 ± NA | -1.15 ± 10.114 |
| Week 84 (n=0,11) | NA ± NA | -2.64 ± 13.493 |
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.
| participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Any Dose Reduction/Interruption/Discontinuation | 3 | 37 |
| Dose Reduction | 1 | 14 |
| Dose Interruption ≤60 Days | 1 | 15 |
| Dose Reduction/Interruption ≤60 Days | 1 | 27 |
| Discontinuation >60 Days | 2 | 15 |
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Any Dose Reduction/Interruption/Discontinuation | 7.3 | 23.0 |
| Dose Reduction | 2.4 | 8.7 |
| Dose Interruption ≤60 Days | 2.4 | 9.3 |
| Dose Reduction/Interruption ≤60 Days | 2.4 | 16.8 |
| Discontinuation >60 Days | 4.9 | 9.3 |
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD dose reduction/interruption ≤60 days were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
| percentage of reasons | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| AEs | 0 | 70.7 |
| Efficacy | 0 | 2.4 |
| Joint Surgery | 0 | 2.4 |
| Medical History | 100.0 | 2.4 |
| RA Improvement | 0 | 7.3 |
| RA Treatment | 0 | 2.4 |
| Replace Previous Drug | 0 | 2.4 |
| Participant Request | 0 | 2.4 |
| Not Specified | 0 | 7.3 |
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD discontinuation were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
| percentage of reasons | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| AEs | 66.7 | 43.8 |
| Efficacy | 33.3 | 0 |
| Investigator Recommendation | 0 | 6.3 |
| RA Improvement | 0 | 31.3 |
| Participant Request | 0 | 6.3 |
| Too Expensive | 0 | 6.3 |
| Not Specified | 0 | 6.3 |
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.
| participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Any Dose Reduction/Interruption/Discontinuation | 6 | 33 |
| Dose Reduction | 5 | 24 |
| Dose Interruption ≤14 Days | 0 | 2 |
| Discontinuation >14 Days | 2 | 19 |
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Any Dose Reduction/Interruption/Discontinuation | 40.0 | 37.1 |
| Dose Reduction | 33.3 | 27.0 |
| Dose Interruption ≤14 Days | 0 | 2.2 |
| Discontinuation >14 Days | 13.3 | 21.3 |
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose reduction were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
| percentage of reasons | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| AEs | 0 | 3.6 |
| Medical History | 42.9 | 0 |
| RA Treatment | 0 | 2.4 |
| Steroid Tapering | 50.0 | 91.7 |
| Participant Request | 0 | 1.2 |
| Not Specified | 7.1 | 1.2 |
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose interruption ≤14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
| percentage of reasons | SC TCZ QW |
|---|---|
| Hospitalization | 33.3 |
| Steroid Tapering | 66.7 |
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS discontinuation \>14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
| percentage of reasons | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| AE Resolution | 0 | 18.5 |
| AEs | 50.0 | 11.1 |
| Prescription End | 0 | 14.8 |
| RA Improvement | 0 | 14.8 |
| Steroid Tapering | 50.0 | 18.5 |
| Participant Request | 0 | 7.4 |
| Not Specified | 0 | 14.8 |
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was reported.
| participants | SC TCZ/All Participants |
|---|---|
| Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen | 14 |
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The percentage of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was calculated.
| percentage of participants | SC TCZ/All Participants |
|---|---|
| Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen | 6.5 |
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and thereafter returned to the QW regimen was reported with the reason for returning to the QW regimen.
| participants | SC TCZ/All Participants |
|---|---|
| Any Reason | 1 |
| Investigator Recommendation | 1 |
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. Time to return was defined as the time between switching to the Q2W regimen and returning to the previous QW regimen.
| weeks | SC TCZ/All Participants |
|---|---|
| Time to Return to the QW Regimen After Switching to the Q2W Regimen | 20 |
The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms.
| mm | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 39.39 ± 24.483 | 47.25 ± 29.868 |
| Week 12 (n=44,172) | 31.80 ± 23.878 | 37.84 ± 28.130 |
| Week 24 (n=43,168) | 31.86 ± 25.639 | 37.51 ± 27.536 |
| Week 36 (n=39,159) | 30.13 ± 23.345 | 37.44 ± 27.519 |
| Week 48 (n=18,141) | 37.95 ± 24.878 | 34.63 ± 27.136 |
| Week 60 (n=2,92) | 54.00 ± 24.042 | 32.86 ± 27.932 |
| Week 72 (n=1,52) | 57.00 ± NA | 30.83 ± 28.425 |
| Week 84 (n=0,11) | NA ± NA | 30.00 ± 26.348 |
The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in perceived disease activity.
| mm | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,172) | -7.59 ± 22.689 | -9.59 ± 22.348 |
| Week 24 (n=43,168) | -6.67 ± 18.977 | -9.67 ± 26.260 |
| Week 36 (n=39,159) | -11.59 ± 23.736 | -10.14 ± 25.338 |
| Week 48 (n=18,141) | -5.61 ± 21.892 | -11.47 ± 25.839 |
| Week 60 (n=2,92) | 11.50 ± 30.406 | -9.93 ± 22.992 |
| Week 72 (n=1,52) | 19.00 ± NA | -13.82 ± 25.779 |
| Week 84 (n=0,11) | NA ± NA | -10.82 ± 19.778 |
The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain.
| mm | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 36.89 ± 23.044 | 45.42 ± 29.448 |
| Week 12 (n=44,172) | 29.30 ± 22.782 | 33.27 ± 25.984 |
| Week 24 (n=43,168) | 29.42 ± 24.509 | 34.48 ± 24.841 |
| Week 36 (n=39,159) | 28.38 ± 20.607 | 34.40 ± 25.149 |
| Week 48 (n=18,141) | 33.44 ± 21.742 | 31.52 ± 25.892 |
| Week 60 (n=2,92) | 50.00 ± 14.142 | 30.94 ± 27.635 |
| Week 72 (n=1,52) | 42.00 ± NA | 29.20 ± 26.733 |
| Week 84 (n=0,11) | NA ± NA | 25.36 ± 25.598 |
The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in pain.
| mm | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,172) | -7.59 ± 22.145 | -12.27 ± 21.582 |
| Week 24 (n=43,168) | -6.63 ± 20.641 | -10.76 ± 24.154 |
| Week 36 (n=39,159) | -10.62 ± 22.783 | -10.91 ± 22.747 |
| Week 48 (n=18,141) | -8.00 ± 18.166 | -12.91 ± 24.950 |
| Week 60 (n=2,92) | 3.00 ± 25.456 | -10.07 ± 22.001 |
| Week 72 (n=1,52) | 3.00 ± NA | -12.47 ± 23.522 |
| Week 84 (n=0,11) | NA ± NA | -14.64 ± 20.911 |
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 0.98 ± 0.682 | 1.20 ± 0.729 |
| Week 12 (n=44,172) | 0.95 ± 0.688 | 1.11 ± 0.750 |
| Week 24 (n=43,167) | 0.94 ± 0.717 | 1.09 ± 0.725 |
| Week 36 (n=39,159) | 0.95 ± 0.682 | 1.10 ± 0.741 |
| Week 48 (n=18,141) | 0.97 ± 0.596 | 1.04 ± 0.745 |
| Week 60 (n=2,92) | 2.13 ± 0.530 | 1.01 ± 0.779 |
| Week 72 (n=1,52) | 2.25 ± NA | 0.97 ± 0.844 |
| Week 84 (n=0,11) | NA ± NA | 1.14 ± 0.730 |
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The change from Baseline to each visit was calculated, where positive changes represent an increased need for assistance with daily activities.
| units on a scale | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Week 12 (n=44,172) | -0.02 ± 0.254 | -0.10 ± 0.339 |
| Week 24 (n=43,167) | -0.01 ± 0.272 | -0.11 ± 0.372 |
| Week 36 (n=39,159) | -0.08 ± 0.276 | -0.09 ± 0.394 |
| Week 48 (n=18,141) | -0.01 ± 0.237 | -0.14 ± 0.390 |
| Week 60 (n=2,92) | 0.56 ± 0.795 | -0.08 ± 0.394 |
| Week 72 (n=1,52) | 0.88 ± NA | -0.06 ± 0.420 |
| Week 84 (n=0,11) | NA ± NA | -0.07 ± 0.397 |
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The percentage of participants achieving a score \<0.5 was calculated at each visit.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline (n=44,173) | 31.8 | 17.9 |
| Week 12 (n=44,172) | 27.3 | 20.9 |
| Week 24 (n=43,167) | 32.6 | 23.4 |
| Week 36 (n=39,159) | 38.5 | 24.5 |
| Week 48 (n=18,141) | 27.8 | 24.8 |
| Week 60 (n=2,92) | 0.0 | 29.3 |
| Week 72 (n=1,52) | 0.0 | 34.6 |
| Week 84 (n=0,11) | NA | 9.1 |
Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The number of participants who met criteria for low disease activity was reported at each visit.
| participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline, DAS28 (n=44,172) | 11 | 46 |
| Baseline, SDAI (n=44,170) | 14 | 43 |
| Baseline, CDAI (n=44,173) | 13 | 41 |
| Week 12, DAS28 (n=44,172) | 21 | 81 |
| Week 12, SDAI (n=44,172) | 22 | 65 |
| Week 12, CDAI (n=44,172) | 20 | 63 |
| Week 24, DAS28 (n=43,168) | 23 | 82 |
| Week 24, SDAI (n=41,166) | 19 | 67 |
| Week 24, CDAI (n=42,166) | 20 | 60 |
| Week 36, DAS28 (n=39,159) | 21 | 75 |
| Week 36, SDAI (n=39,159) | 20 | 61 |
| Week 36, CDAI (n=39,159) | 21 | 60 |
| Week 48, DAS28 (n=18,141) | 10 | 69 |
| Week 48, SDAI (n=18,140) | 8 | 63 |
| Week 48, CDAI (n=18,140) | 7 | 59 |
| Week 60, DAS28 (n=2,92) | 0 | 52 |
| Week 60, SDAI (n=2,92) | 0 | 40 |
| Week 60, CDAI (n=2,92) | 0 | 37 |
| Week 72, DAS28 (n=1,52) | 0 | 28 |
| Week 72, SDAI (n=1,52) | 0 | 26 |
| Week 72, CDAI (n=1,52) | 0 | 25 |
| Week 84, DAS28 (n=0,11) | NA | 6 |
| Week 84, SDAI (n=0,11) | NA | 4 |
| Week 84, CDAI (n=0,11) | NA | 4 |
Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for low disease activity was calculated at each visit.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline, DAS28 (n=44,172) | 25.0 | 26.7 |
| Baseline, SDAI (n=44,170) | 31.8 | 25.3 |
| Baseline, CDAI (n=44,173) | 29.5 | 23.7 |
| Week 12, DAS28 (n=44,172) | 47.7 | 47.1 |
| Week 12, SDAI (n=44,172) | 50.0 | 37.8 |
| Week 12, CDAI (n=44,172) | 45.5 | 36.6 |
| Week 24, DAS28 (n=43,168) | 53.5 | 48.8 |
| Week 24, SDAI (n=41,166) | 46.3 | 40.4 |
| Week 24, CDAI (n=42,166) | 47.6 | 36.1 |
| Week 36, DAS28 (n=39,159) | 53.8 | 47.2 |
| Week 36, SDAI (n=39,159) | 51.3 | 38.4 |
| Week 36, CDAI (n=39,159) | 53.8 | 37.7 |
| Week 48, DAS28 (n=18,141) | 55.6 | 48.9 |
| Week 48, SDAI (n=18,140) | 44.4 | 45.0 |
| Week 48, CDAI (n=18,140) | 38.9 | 42.1 |
| Week 60, DAS28 (n=2,92) | 0.0 | 56.5 |
| Week 60, SDAI (n=2,92) | 0.0 | 43.5 |
| Week 60, CDAI (n=2,92) | 0.0 | 40.2 |
| Week 72, DAS28 (n=1,52) | 0.0 | 53.8 |
| Week 72, SDAI (n=1,52) | 0.0 | 50.0 |
| Week 72, CDAI (n=1,52) | 0.0 | 48.1 |
| Week 84, DAS28 (n=0,11) | NA | 54.5 |
| Week 84, SDAI (n=0,11) | NA | 36.4 |
| Week 84, CDAI (n=0,11) | NA | 36.4 |
Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The number of participants who met criteria for remission was reported at each visit.
| participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline, DAS28 (n=44,172) | 6 | 33 |
| Baseline, SDAI (n=44,170) | 2 | 15 |
| Baseline, Boolean (n=44,172) | 1 | 14 |
| Week 12, DAS28 (n=44,172) | 14 | 61 |
| Week 12, SDAI (n=44,172) | 7 | 20 |
| Week 12, Boolean (n=44,172) | 4 | 15 |
| Week 24, DAS28 (n=43,168) | 18 | 61 |
| Week 24, SDAI (n=41,166) | 8 | 23 |
| Week 24, Boolean (n=43,170) | 5 | 16 |
| Week 36, DAS28 (n=39,159) | 15 | 57 |
| Week 36, SDAI (n=39,159) | 7 | 21 |
| Week 36, Boolean (n=39,161) | 3 | 17 |
| Week 48, DAS28 (n=18,141) | 9 | 51 |
| Week 48, SDAI (n=18,140) | 1 | 15 |
| Week 48, Boolean (n=18,143) | 1 | 14 |
| Week 60, DAS28 (n=2,92) | 0 | 39 |
| Week 60, SDAI (n=2,92) | 0 | 17 |
| Week 60, Boolean (n=2,93) | 0 | 14 |
| Week 72, DAS28 (n=1,52) | 0 | 22 |
| Week 72, SDAI (n=1,52) | 0 | 11 |
| Week 72, Boolean (n=1,54) | 0 | 10 |
| Week 84, DAS28 (n=0,11) | NA | 6 |
| Week 84, SDAI (n=0,11) | NA | 2 |
| Week 84, Boolean (n=0,11) | NA | 2 |
Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for remission was calculated at each visit.
| percentage of participants | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Baseline, DAS28 (n=44,172) | 13.6 | 19.2 |
| Baseline, SDAI (n=44,170) | 4.5 | 8.8 |
| Baseline, Boolean (n=44,172) | 2.3 | 8.1 |
| Week 12, DAS28 (n=44,172) | 31.8 | 35.5 |
| Week 12, SDAI (n=44,172) | 15.9 | 11.6 |
| Week 12, Boolean (n=44,172) | 9.1 | 8.7 |
| Week 24, DAS28 (n=43,168) | 41.9 | 36.3 |
| Week 24, SDAI (n=41,166) | 19.5 | 13.9 |
| Week 24, Boolean (n=43,170) | 11.6 | 9.4 |
| Week 36, DAS28 (n=39,159) | 38.5 | 35.8 |
| Week 36, SDAI (n=39,159) | 17.9 | 13.2 |
| Week 36, Boolean (n=39,161) | 7.7 | 10.6 |
| Week 48, DAS28 (n=18,141) | 50.0 | 36.2 |
| Week 48, SDAI (n=18,140) | 5.6 | 10.7 |
| Week 48, Boolean (n=18,143) | 5.6 | 9.8 |
| Week 60, DAS28 (n=2,92) | 0.0 | 42.4 |
| Week 60, SDAI (n=2,92) | 0.0 | 18.5 |
| Week 60, Boolean (n=2,93) | 0.0 | 15.1 |
| Week 72, DAS28 (n=1,52) | 0.0 | 42.3 |
| Week 72, SDAI (n=1,52) | 0.0 | 21.2 |
| Week 72, Boolean (n=1,54) | 0.0 | 18.5 |
| Week 84, DAS28 (n=0,11) | NA | 54.5 |
| Week 84, SDAI (n=0,11) | NA | 18.2 |
| Week 84, Boolean (n=0,11) | NA | 18.2 |
Collected over From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SC TCZ Q2W | — | 4/44 (9.1%) | 22/44 (50%) |
| SC TCZ QW | — | 19/173 (11%) | 102/173 (59%) |
| Event | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| EndophthalmitisInfections and infestations | 1/44 | 0/173 |
| PyelonephritisInfections and infestations | 1/44 | 0/173 |
| SyncopeNervous system disorders | 1/44 | 1/173 |
| Abdominal compartment syndromeGastrointestinal disorders | 1/44 | 0/173 |
| Deep vein thrombosisVascular disorders | 1/44 | 0/173 |
| Endometrial stromal sarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/44 | 0/173 |
| HaematuriaRenal and urinary disorders | 1/44 | 0/173 |
| CellulitisInfections and infestations | 0/44 | 2/173 |
| Staphylococcal bacteraemiaInfections and infestations | 0/44 | 2/173 |
| Transient ischaemic attackNervous system disorders | 0/44 | 2/173 |
| Event | SC TCZ Q2W | SC TCZ QW |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/44 | 35/173 |
| SinusitisInfections and infestations | 2/44 | 22/173 |
| NasopharyngitisInfections and infestations | 2/44 | 20/173 |
| Urinary tract infectionInfections and infestations | 2/44 | 15/173 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/44 | 12/173 |
| Alanine aminotransferase increasedInvestigations | 0/44 | 12/173 |
| FallInjury, poisoning and procedural complications | 3/44 | 6/173 |
| ContusionInjury, poisoning and procedural complications | 3/44 | 5/173 |
| DiarrhoeaGastrointestinal disorders | 3/44 | 8/173 |
| RashSkin and subcutaneous tissue disorders | 3/44 | 6/173 |
Safety Population: All participants who received at least one dose of study medication and had at least one post-dose safety assessment.
| Age, Continuous(years) | SC TCZ Q2W | SC TCZ QW | Total |
|---|---|---|---|
| Mean | 59.7 ± 10.18 | 58.1 ± 10.38 | 58.4 ± 10.33 |
| Sex: Female, Male(Participants) | SC TCZ Q2W | SC TCZ QW | Total |
|---|---|---|---|
| Female | 33 | 133 | 166 |
| Male | 11 | 40 | 51 |
The record gives a start of Aug 2012, a primary completion of Apr 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab